Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results
2015 | 28 | 3 | 176-180

Article title

Omentin - a new adipokine with many roles to play


Title variants

Languages of publication



Adipose tissue is at a point of high interest in medical research, not only as an energy depot, but also because it secretes nearly more than 600 cytokines. These are termed‚ adipokines’. Human adipokines are involved in numerous metabolic processes, including the regulation of appetite, energy expenditure, insulin sensitivity, inflammation and cardiovascular activity. Thus, these could be clinically important as a markers of adipose tissue function and increased metabolic risk. The search for novel adipokines linking obesity to related co-morbidities has become a major topic in obesity research. In such work, there is an increasing need to define their function, their molecular targets and their potential clinical relevance as biomarkers or in the treatment of obesity and other metabolic diseases. Omentin (34 kDa) is a recently identified fat deposition-specific adipokine with multiple interactions. Concentrations of omentin have been shown to be decreased in patients with obesity and impaired glucose regulation, in patients afflicted with diabetes type 1 and 2, and in patients with polycystic ovary syndrome. These are all diseases commonly associated with insulin resistance and obesity. The aim of this study was to show and compare the latest information about omentin and its relationships with obesity, diabetes mellitus (DM), metabolic syndrome (MetS), inflammation, cardiac problems, sex hormone imbalances and cancer. The association of omentin with particular metabolic indexes may suggest that an elevation in omentin level may be seen as being a marker for leanness, while a decreased level will underline possible situations of overweight and obesity along with their comorbidities (diabetes, cardiovascular disease, metabolic syndrome, inflammation and even cancer). However, a challenge for the future is to fully understand the multiple role played by omentin. Thus, more studies in these matter are required.









Physical description


1 - 9 - 2015
15 - 1 - 2015
15 - 9 - 2015
26 - 11 - 2015


  • Department of Laboratory Diagnostics, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland
  • Department of Laboratory Diagnostics, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland
  • Chair and department of Human Physiology, Medical University of Lublin, Radziwillowska 11, 20-080 Lublin, Poland
  • Department of Laboratory Diagnostics, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland
  • Department of Laboratory Diagnostics, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland


  • 1. Akbarzadeh S., Ghasemi S., Kalantarhormozi M., et al.: Relationship among plasma adipokines, insulin and androgens level, as well as biochemical glycemic and lipidemic markers with incidence of PCOS in woman with normal BMI. Gynecol. Endocrinol., 28, 7, 2012.[Crossref]
  • 2. Alcelik A., Tosun M., Ozlu M. F., et al.: Serum levels of omentin in end-stage renal disease patients. Kidney Blood Press. Res., 35, 6, 2012.
  • 3. Bastard J., Maachi M., Lagathu C. et al.: Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw., 17, 1, 2006.
  • 4. Bluher M.: Adipose Tissue Dysfunction in Obesity. Exp. Clin. Endocrinol. Diabetes, 117, 6, 2009.[Crossref]
  • 5. Bremer A. A., Jialal I.: Adipose tissue dysfunction in nascent metabolic syndrome. J. Obes., ID 393192, 2013. (Epub)
  • 6. Calle E. E., Thun M. J.: Obesity and cancer. Oncogene, 23, 38, 2004.[Crossref]
  • 7. Choi J. H., Rhee E. J., Kim K. H., et al.: Plasma omentin-1 levels are reduced in non-obese woman with normal glucose tolerance and polycystic ovary syndrome. Eur. J. Endocrinol., 165, 5, 2011.
  • 8. Couillard C., Ruel G., Archer W. R., et al.: Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. J. Clin. Endocrinol. Metab., 90, 12, 2005.[Crossref]
  • 9. De Pergola G., Silvestris F.: Obesity as a major risk for cancer. J. Obes., 2013:291546, 2013. (Epub)
  • 10. De Souza Batista C. M., Yang R. Z., Lee M. J. et al.: Omentin plasma levels and gene expression are decreased in obesity. Diabetes, 56, 6, 2007.[Crossref][WoS]
  • 11. Fazeli M. S., Dashti H., Akbarzadeh S., et al.: Circulating levels of novel adipocytokines in patients with colorectal cancer. Cytokine, 62, 1, 2013.[WoS][Crossref]
  • 12. Flehmig G., Scholz M., Kloting N. et al.: Identification of Adipokine Clusters Related to Parameters of Fat Mass, Insulin Sensitivity and Inflammation. PLoS One, 9, 6, 2014.
  • 13. Hotamisligil G.S.: Inflammation and metabolic disorders. Nature, 444 (860-867), 2006.
  • 14. Katsi V., Vamvakou G., Lekakis J., et al.: Omentin, Fat and Heart: Classical Music with New Instruments. Heart, Lung and Circulation, 23, 9, 2014.
  • 15. Kloting N., Fasshauer M., Dietrich A. et al.: Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab., 299, 3, 2010.
  • 16. Lehr S., Hartwig S., Sell H.: Adipokines: a treasure trove for discovery of biomarkers for metabolic disorders. Proteomics Clin. Appl., 6, 1-2, 2012.[WoS][Crossref]
  • 17. Liu R., Wang X., Bu P.: Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res. Clin. Pract., 93, 1, 2011.[WoS]
  • 18. Luque-Ramirez M., Martinez-Garcia M. A., Montes-Nieto R., et al.: Sexual dimorphism in adipose tissue function as evidenced by circulating adipokine concentrations in the fasting state and after an oral glucose challenge. Hum. Reprod., 28, 7, 2013.[WoS]
  • 19. Mahde A., Shaker M., Al-Mashhadani Z. Study of omentin-1 and other adipokines and hormones in PCOS patient. OMJ, 24, 2, 2009.
  • 20. Moreno-Navarrete J. M., Catalan V., Ortega F. at al.: Circulating omentin concentration increases after weight loss. Nutr. Metab., 7, 27, 2010.[WoS]
  • 21. Moreno-Navarrete J. M., Ortega F., Castro A. et al.: Circulating Omentin as a Novel Biomarker of Endothelial Dysfunction. Obesity, 19, 8, 2011.[WoS]
  • 22. Oświęcimska J., Suwała A., Świętochowska E. et al.: Serum omentin levels in adolescent girls with anorexia nervosa and obesity. Physiol. Res., 2015. (Epub)
  • 23. Otake S., Takeda H., Fujishima S., et al.: Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J. Gastroenterol., 16, 10, 2010.[WoS]
  • 24. Pan H. Y., Guo L., Li Q.: Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res. Clin. Pract., 88, 1, 2010.[WoS][Crossref]
  • 25. Ridker P. M., Buring J. E., Cook N. R., et al.: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation, 107, 3, 2003.[Crossref]
  • 26. Schaffler A., Neumeier M., Herfarth H., et al.: Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim. Biophys. Acta, 1732, 1-3, 2005.
  • 27. Schaffler A., Zeitoun M., Wobser H. et al.: Frequency and significance of the novel single nucleotide missense polymorphism Val109Asp in humangene encoding omentin in Caucasian patients with type 2 diabetes mellitus or chronic inflammatory bowel disease. Cardiovasc. Diabetol., 6, 3, 2007.
  • 28. Senolt L., Polanska M., Filkova M. et al.: Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis. Ann. Rheum. Dis., 69, doi:10.1136/ ard.2009.119735, 2010.[WoS][Crossref]
  • 29. Shetty G. K., Economides P. A., Horton E. S. at al.: Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care, 27, 10, 2004.[Crossref]
  • 30. Tan B. K., Adya R., Farhatullah S. et al.: Omentin-1, a novel adipokine, is decreased in overweight insulin resistant woman with the polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes, 57, 4, 2008.
  • 31. Tan B. K., Adya R., Farhatullah S., et al.: Metformin treatment may increase omentin-1 levels in woman with polycystic ovary syndrome. Diabetes, 59, 12, 2010.[Crossref]
  • 32. Tan B. K., Adya R., Randeva H. S.: Omentin: A Novel Link Between Inflammation, Diabesity, and Cardiovascular Disease. TCM, 20, 5, 2010.
  • 33. Tan B. K., Pua S., Syed F., et al.: Decreased plasma omentin-1 levels in Type 1 diabetes mellitus. Diabet. Med., 25, 10, 2008.[Crossref]
  • 34. Thanyasiri P., Celermajer D. S., Adams M. R., et al.: Endothelial dysfunction occurs in peripheral circulation patients with acute and stable coronary artery disease. Am. J. Physiol. Heart Circ. Physiol., 289, 2, 2005.
  • 35. Tonjes A., Fasshauer M., Kratzsch J. et al.: Adipokine Pattern in Subjects with Impaired Fasting Glucose and Impaired Glucose Tolerance in Comparison to Normal Glucose Tolerance and Diabetes. PLoS One, 5, 11, 2010.
  • 36. Uyeturk U., Sarici H., Tekce B. K. et al.: Serum omentin level in patients with prostate cancer. Med. Oncol., 31, 4, 2014.[WoS][Crossref]
  • 37. Van Gall L. F., Mertens I. L., de Block C. E.: Mechanisms linking obesity with cardiovascular disease. Nature, 444 (875-880), 2006.
  • 38. Vu A., Sidhom M. S., Bredbeck B. C., et al.: Evaluation of the relationship between circulating omentin-1 concentrations and components of the metabolic syndrome in adults without type 2 diabetes or cardiovascular disease. Diabetology & Metabolic Syndrome, 6, 4, 2014.[WoS]
  • 39. Wada J.: Vaspin: A novel serpin with insulin-sensitizing effects. Expert Opin. Inv. Drug, 17, 2008.
  • 40. Weisberg S. P., McCann D., Desai M., et al.: Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest., 112, 12, 2003.[Crossref]
  • 41. Xu L., Zhu G. B., Wang L., et al.: Synovial fluid omentin-1 levels are inversely correlated with radiographic severity of knee osteoarthritis. J. Investing Med., 60, 3, 2012.
  • 42. Yamawaki H. Tsubaki N., Mukohda M. et al.: Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem. Biophys. Res. Commun., 393, 4, 2010.[WoS]
  • 43. Yamawaki H.: Vascular effects of novel adipokines: focus on vascular contractility and inflammatory responses. Biol. Pharm. Bull., 34, 3, 2011.[Crossref]
  • 44. Yan P., Liu D., Long M., et al.: Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes, 119, 4, 2011.[Crossref][WoS]
  • 45. Yang R. Z., Lee M. J. Hu H. et al.: Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab., 290, 6, 2006.
  • 46. Zhang Y.Y., Zou L.M.: Omentin-1, new adipokine, promotes apoptosis through regulating Sirt1-dependant p53 deacetylation in hepatocellular carcinoma cells. Eur. J. Pharmacol., 698, 1-3, 2013.
  • 47. Zheng L., Weng M., Qi M., et al.: Aberrant expression of intelectin-1 in gastric cancer: its relationship with clinicopathological features and prognosis. J. Cancer Res. Clin. Oncol., 138, 1, 2012.[WoS]
  • 48. Zhong X., Li X., Liu F., et al.: Omentin inhibits TNF-α-induced expression of adhesion molecules in endothelial cells via ERK/NK-κB pathway. Biochem. Biophys. Res. Commun., 425, 2, 2012.[WoS]
  • 49. Zhong X., Zhang H., Tan H. et al.: Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacologica Sinica, 32, 7, 2011. [WoS][Crossref]

Document Type

Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.